Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
HUTCHMED (China) Ltd (ADR) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
HCM
Nasdaq
2834
https://www.hutch-med.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for HUTCHMED (China) Ltd (ADR)
HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years
- Apr 24th, 2024 9:11 am
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
- Apr 5th, 2024 8:30 am
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
- Apr 2nd, 2024 4:30 am
Do Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?
- Mar 28th, 2024 7:26 am
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
- Mar 28th, 2024 12:00 am
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
- Mar 22nd, 2024 12:00 am
HUTCHMED (China) Full Year 2023 Earnings: EPS: US$0.12 (vs US$0.43 loss in FY 2022)
- Mar 1st, 2024 6:00 am
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
- Feb 28th, 2024 11:30 am
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
- Feb 7th, 2024 12:00 am
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
- Feb 2nd, 2024 8:30 am
HUTCHMED to Announce 2023 Final Results
- Feb 1st, 2024 8:30 am
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
- Jan 30th, 2024 4:53 am
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
- Jan 11th, 2024 12:00 am
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
- Dec 13th, 2023 4:30 am
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
- Dec 13th, 2023 12:00 am
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
- Dec 1st, 2023 12:00 am
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
- Nov 10th, 2023 1:35 pm
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
- Nov 9th, 2023 12:11 am
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
- Nov 1st, 2023 12:35 pm
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023
- Nov 1st, 2023 12:35 am
Scroll